BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots and patients with varicose veins in the great saphenous vein system of the leg. Its Specialty Pharmaceutical products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. Its Licensing business area consists of licensed products and programs and generates royalties for the company. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd, BTG Employee Share Schemes Ltd and other.